The estimated Net Worth of John M Leonard is at least 20.1 百万$ dollars as of 3 January 2024. Dr Leonard owns over 19,223 units of Intellia Therapeutics Inc stock worth over 17,132,877$ and over the last 12 years he sold NTLA stock worth over 2,089,729$. In addition, he makes 912,786$ as Pres、 CEO & Director at Intellia Therapeutics Inc.
Dr has made over 30 trades of the Intellia Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 19,223 units of NTLA stock worth 566,310$ on 3 January 2024.
The largest trade he's ever made was exercising 317,060 units of Intellia Therapeutics Inc stock on 1 February 2021 worth over 4,806,630$. On average, Dr trades about 20,163 units every 75 days since 2013. As of 3 January 2024 he still owns at least 846,486 units of Intellia Therapeutics Inc stock.
You can see the complete history of Dr Leonard stock trades at the bottom of the page.
Dr. John M. Leonard is the Pres, CEO & Director at Intellia Therapeutics Inc.
As the Pres、 CEO & Director of Intellia Therapeutics Inc, the total compensation of Dr Leonard at Intellia Therapeutics Inc is 912,786$. There are 2 executives at Intellia Therapeutics Inc getting paid more, with Laura Sepp-Lorenzino having the highest compensation of 1,762,490$.
Dr Leonard is 64, he's been the Pres、 CEO & Director of Intellia Therapeutics Inc since . There are 2 older and 17 younger executives at Intellia Therapeutics Inc. The oldest executive at Intellia Therapeutics Inc is Jesse Goodman, 68, who is the Independent Director.
John's mailing address filed with the SEC is C/O IQVIA HOLDINGS INC., 2400 ELLIS ROAD, DURHAM, NC, 27703.
Over the last 9 years, insiders at Intellia Therapeutics Inc have traded over 210,567,884$ worth of Intellia Therapeutics Inc stock and bought 1,285,277 units worth 23,117,886$ . The most active insiders traders include Carl L Gordon、Jean Francois Formela、Bros. Advisors Lpbaker Feli.... On average, Intellia Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of 1,357,638$. The most recent stock trade was executed by Eliana Clark on 1 July 2024, trading 405 units of NTLA stock currently worth 9,287$.
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Intellia Therapeutics Inc executives and other stock owners filed with the SEC include: